Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04671251 · ClinicalTrials.gov registry record · Phase 1
Phase 1b Study of AEVI-007 in Subjects With Relapsed or Refractory Multiple Myeloma
A Phase 1 study, sponsored by Avalo Therapeutics.
- Completed
- Registry status
- Phase 1
- Development phase
- 13
- Enrollment target
NCT04671251 is a Phase 1 study that has completed, run by Avalo Therapeutics. The registered enrollment target is 13 participants.
The verdict
NCT04671251, a Phase 1 study, has completed, sponsored by Avalo Therapeutics.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 13 participants
- Enrollment target
Study Summary
This is a multicenter, open-label, dose-escalation Phase 1b study of AEVI-007 in subjects with relapsed or refractory Multiple Myeloma. The objectives of the study are to evaluate the safety, pharmacokinetics and pharmacodynamics of AEVI-007.
Interventions
- DRUG AEVI-007
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 13 participants |
| Start Date | 2020-12-15 |
| Est. Completion | 2022-03-30 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04671251
The ClinicalTrials.gov registry entry for NCT04671251 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 13 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Avalo Therapeutics, which has 8 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which AEVI-007 is the first listed.
NCT04671251 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04671251 about?
NCT04671251 is a clinical study titled "Phase 1b Study of AEVI-007 in Subjects With Relapsed or Refractory Multiple Myeloma". This is a multicenter, open-label, dose-escalation Phase 1b study of AEVI-007 in subjects with relapsed or refractory Multiple Myeloma. The objectives of the study are to evaluate the safety, pharmacokinetics and pharmacodynamics of AEVI-007.
What is the current status of trial NCT04671251?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 13 participants. The study started on 2020-12-15. Estimated completion is 2022-03-30.
What interventions are being tested in trial NCT04671251?
The interventions under investigation include: AEVI-007 (DRUG).
Who is sponsoring clinical trial NCT04671251?
This trial is sponsored by Avalo Therapeutics, which has 8 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.